MedTrace Logo

Assessment of ProEnkephalin to Detect Acute Kidney Injury (AKI)

NCT04019314 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-08-23

No results posted yet for this study

Summary

Researchers are observing the values of proEnkephalin (PENK) via a blood draw in hospitalized patients that are volume overloaded requiring diuresis. If changes in PENK are found, physicians may predict values of change in kidney function during treatment.

Conditions

  • Heart Failure
  • Volume Overload
  • Decompensated Heart Failure
  • Systolic Heart Failure

Interventions

PROCEDURE

Blood Collection

Samples for proEnkephalin PENK will be obtained daily and aliquots of these samples will be stored for later batch assays.

PROCEDURE

Blood Volume Analysis

A small amount of a radioactive isotope or tracer is injected and blood samples are taken at 6 time points during the test and analyzed.

Sponsors & Collaborators

  • Sphingotec GmbH

    collaborator INDUSTRY

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Wayne Miller, MD · Mayo Clinic

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-11
Primary Completion
2021-10-06
Completion
2021-10-06

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04019314 on ClinicalTrials.gov